Printer Friendly

Vitamin E protects patients from cisplatin-induced neuropathy in a randomized trial.

Reference: Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy. Neurology 2010;74:762-6.

Design: Randomized double blind intervention trial

Participants: Of 108 patients initially randomized in the trial, 41 were treated with cisplatin exceeding 300 mg/[m.sup.2]. Of these 41 subjects, 17 had been given vitamin E and 24 had been given placebo.

Study Medication and Dosage: 596 IU d-alpha tocopherol or placebo daily, begun 1 to 8 days before the start of cisplatin therapy and continued for 3 months following discontinuation of cisplatin therapy

Outcome Measures: Development of peripheral neuropathy as a result of cisplatin therapy and measurement of the severity of the neurological damage through the use of Total Neuropathy Score (TNS)

Key Findings: Neurotoxicity occurred in 6% in the vitamin E group versus 42% in the placebo group (p < 0.01). The severity of neurological damage was also far lower in the vitamin E group (1.4 TNS versus 4.1; p < 0.01).

Practice Implications: Cisplatin use is limited by severe neurotoxicity. When the cumulative dose exceeds 300 mg/[m.sup.2], in some reports most patients suffer significant neurological damage. Cisplatin is known to increase oxidative stress, vitamin E is an antioxidant, and current evidence suggests that the antioxidant actions of vitamin E do not interfere with the therapeutic effect of chemotherapy (Int J Cancer 2003;104:243-50). Neuropathy has been reported to occur as part of the presentation of vitamin E deficiency. As a result, researchers are interested in exploring the ability of vitamin E to protect against cisplatin-induced neuropathies.

In 2007, a Cochrane review concluded that previous evidence linking the use of vitamin E to protection against neuropathy in patients given cisplatin was encouraging but needed additional support from randomized clinical trials (Cochrane Database Syt Rev 2007;1:CD005228). The findings of the new trial take us a significant step in that direction. Until more is known, all patients given cisplatin should concomitantly take vitamin E supplements beginning several days before the start of the chemotherapy.

by: Steve Austin, N.D.

Submitted by: Emerson Ecologics

COPYRIGHT 2010 Original Internist, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Abstracts of Interest
Author:Austin, Steve
Publication:Original Internist
Geographic Code:1USA
Date:Sep 1, 2010
Words:350
Previous Article:St. John's Wort for menopausal symptoms.
Next Article:Oral magnesium again reported to help asthma sufferers in a randomized trial.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters